Results 321 to 330 of about 838,175 (338)

PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.

Journal of Clinical Oncology, 2014
L. Schwartzberg, F. Rivera, M. Karthaus, G. Fasola, J. Canon, J. Hecht, Hua Yu, K. Oliner, W. Go   +8 more
semanticscholar   +1 more source

A non-AUG translational initiation in c-myc exon 1 generates an N-terminally distinct protein whose synthesis is disrupted in Burkitt's lymphomas

Cell, 1988
Michael W King
exaly  

Exon

2012
openaire   +1 more source

Multiple exon-binding sites in class II self-splicing introns

Cell, 1987
Alain Jacquier
exaly  

Exon

2004
Niall Dillon, Laszlo Patthy
openaire   +1 more source

FDA approves first EGFR exon 20 targeted kinase inhibitor

Nature Reviews Drug Discovery, 2021
exaly  

Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study

Lancet, The, 2011
Sebahattin Cirak, V Arechavala-Gomeza, Michela Guglieri   +2 more
exaly  

Exonization

2008
openaire   +1 more source

Exon

2017
openaire   +1 more source

"Exoner"

Notes and Queries, 1901
openaire   +1 more source